Search Results - Henley, Jill E

  • Showing 1 - 6 results of 6
Refine Results
  1. 1
    Novel Arenavirus Entry Inhibitors Discovered by Using a Minigenome Rescue System for High-Throughput Drug Screening

    Novel Arenavirus Entry Inhibitors Discovered by Using a Minigenome Rescue System for High-Throughput Drug Screening by Rathbun, Jessica Y, Droniou, Magali E, Damoiseaux, Robert, Haworth, Kevin G, Henley, Jill E, Exline, Colin M, Choe, Hyeryun, Cannon, Paula M

    Published in Journal of virology
    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  2. 2
    Comparison of SARS-CoV-2 entry inhibitors based on ACE2 receptor or engineered Spike-binding peptides

    Comparison of SARS-CoV-2 entry inhibitors based on ACE2 receptor or engineered Spike-binding peptides by Llewellyn, George N, Chen, Hsu-Yu, Rogers, Geoffrey L, Huang, Xiaoli, Sell, Philip J, Henley, Jill E, Cannon, Paula M

    Published in Journal of virology
    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  3. 3
    Pre-clinical Modeling of CCR5 Knockout in Human Hematopoietic Stem Cells by Zinc Finger Nucleases Using Humanized Mice

    Pre-clinical Modeling of CCR5 Knockout in Human Hematopoietic Stem Cells by Zinc Finger Nucleases Using Humanized Mice by Hofer, Ursula, Henley, Jill E., Exline, Colin M., Mulhern, Orla, Lopez, Evan, Cannon, Paula M.

    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  4. 4
    The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eμ-MYC driven B-cell lymphoma

    The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eμ-MYC driven B-cell lymphoma by Walton, Mike I., Eve, Paul D., Hayes, Angela, Henley, Alan T., Valenti, Melanie R., De Haven Brandon, Alexis K., Box, Gary, Boxall, Kathy J., Tall, Matthew, Swales, Karen, Matthews, Thomas P., McHardy, Tatiana, Lainchbury, Michael, Osborne, James, Hunter, Jill E., Perkins, Neil D., Aherne, G. Wynne, Reader, John C., Raynaud, Florence I., Eccles, Suzanne A., Collins, Ian, Garrett, Michelle D.

    Published in Oncotarget
    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  5. 5
    Supplementation with antioxidants and folinic acid for children with Down’s syndrome: randomised controlled trial

    Supplementation with antioxidants and folinic acid for children with Down’s syndrome: randomised controlled trial by Ellis, Jill M, Tan, Hooi Kuan, Gilbert, Ruth E, Muller, David P R, Henley, William, Moy, Robert, Pumphrey, Rachel, Ani, Cornelius, Davies, Sarah, Edwards, Vanessa, Green, Heather, Salt, Alison, Logan, Stuart

    Published in BMJ
    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  6. 6
    The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eµ-MYC driven B-cell lymphoma

    The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eµ-MYC driven B-cell lymphoma by Walton, Mike I, Eve, Paul D, Hayes, Angela, Henley, Alan T, Valenti, Melanie R, De Haven Brandon, Alexis K, Box, Gary, Boxall, Kathy J, Tall, Matthew, Swales, Karen, Matthews, Thomas P, McHardy, Tatiana, Lainchbury, Michael, Osborne, James, Hunter, Jill E, Perkins, Neil D, Aherne, G Wynne, Reader, John C, Raynaud, Florence I, Eccles, Suzanne A, Collins, Ian, Garrett, Michelle D

    Published in Oncotarget
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: